{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-105953","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.945316+00:00","generated_at":"2026-05-17T00:43:02.742309+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Nuvectis Pharma Q3 net loss $7.5M; cash $35.4M; NXP900 Phase 1b underway","bullets":["Cash $35.4M at Sep 30, 2025, up from $18.5M at Dec 31, 2024; runway into 3Q2027.","Net loss $7.5M (Q3 2025) vs $4.2M (Q3 2024); increase driven by $2.0M NXP900 milestone expense.","R&D expenses $5.8M (Q3 2025) vs $2.8M (Q3 2024), reflecting clinical progress.","NXP900 Phase 1b single-agent portion initiated; combination arm expected by year-end 2025.","Phase 1a dose escalation and drug-drug interaction study completed with pharmacodynamic responses at clinically relevant doses."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-105953","json":"https://secwatch.observer/filing/0001104659-25-105953.json","markdown":"https://secwatch.observer/filing/0001104659-25-105953.md","text":"https://secwatch.observer/filing/0001104659-25-105953.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465925105953/0001104659-25-105953-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465925105953/tm2530070d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:43:02.742309+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}